Boston Biomedical has relocated its headquarters to Cambridge, Massachusetts with the opening of a new 64,000ft2 facility, in a bid to advance its efforts in discovering next generation of targeted cancer therapeutics.
Commenting on the new headquarters, Boston Biomedical chairman and DSP president and CEO Masayo Tada said that the location was surrounded by universities and research institutes that would help capitalize on easy access to advanced scientific research and technology.
Boston Biomedical founder, president, and CEO Dr Chiang J. Li said, "With this facility, and the support of DSP, we intend to make significant progress in translating exciting discoveries in cancer stem cell science into innovative therapeutics for cancer patients."
With support from DSP, Boston Biomedical intends to continue to leverage its scientific expertise and leadership at the new facility to develop novel cancer therapeutics.
